Literature DB >> 24932913

Structure-based virtual screening approach for discovery of covalently bound ligands.

Dora Toledo Warshaviak1, Gali Golan, Kenneth W Borrelli, Kai Zhu, Ori Kalid.   

Abstract

We present a fast and effective covalent docking approach suitable for large-scale virtual screening (VS). We applied this method to four targets (HCV NS3 protease, Cathepsin K, EGFR, and XPO1) with known crystal structures and known covalent inhibitors. We implemented a customized "VS mode" of the Schrödinger Covalent Docking algorithm (CovDock), which we refer to as CovDock-VS. Known actives and target-specific sets of decoys were docked to selected X-ray structures, and poses were filtered based on noncovalent protein-ligand interactions known to be important for activity. We were able to retrieve 71%, 72%, and 77% of the known actives for Cathepsin K, HCV NS3 protease, and EGFR within 5% of the decoy library, respectively. With the more challenging XPO1 target, where no specific interactions with the protein could be used for postprocessing of the docking results, we were able to retrieve 95% of the actives within 30% of the decoy library and achieved an early enrichment factor (EF1%) of 33. The poses of the known actives bound to existing crystal structures of 4 targets were predicted with an average RMSD of 1.9 Å. To the best of our knowledge, CovDock-VS is the first fully automated tool for efficient virtual screening of covalent inhibitors. Importantly, CovDock-VS can handle multiple chemical reactions within the same library, only requiring a generic SMARTS-based predefinition of the reaction. CovDock-VS provides a fast and accurate way of differentiating actives from decoys without significantly deteriorating the accuracy of the predicted poses for covalent protein-ligand complexes. Therefore, we propose CovDock-VS as an efficient structure-based virtual screening method for discovery of novel and diverse covalent ligands.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24932913     DOI: 10.1021/ci500175r

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  34 in total

Review 1.  Docking Screens for Novel Ligands Conferring New Biology.

Authors:  John J Irwin; Brian K Shoichet
Journal:  J Med Chem       Date:  2016-03-15       Impact factor: 7.446

2.  Targeted Covalent Inhibition of Telomerase.

Authors:  Rick C Betori; Yue Liu; Rama K Mishra; Scott B Cohen; Stephen J Kron; Karl A Scheidt
Journal:  ACS Chem Biol       Date:  2020-02-24       Impact factor: 5.100

Review 3.  Selective and Effective: Current Progress in Computational Structure-Based Drug Discovery of Targeted Covalent Inhibitors.

Authors:  Giulia Bianco; David S Goodsell; Stefano Forli
Journal:  Trends Pharmacol Sci       Date:  2020-11-02       Impact factor: 14.819

Review 4.  Covalent inhibition of protein tyrosine phosphatases.

Authors:  Kasi Viswanatharaju Ruddraraju; Zhong-Yin Zhang
Journal:  Mol Biosyst       Date:  2017-06-27

5.  Covalent docking of selected boron-based serine beta-lactamase inhibitors.

Authors:  Jacopo Sgrignani; Beatrice Novati; Giorgio Colombo; Giovanni Grazioso
Journal:  J Comput Aided Mol Des       Date:  2015-02-13       Impact factor: 3.686

6.  Covalent docking in CDOCKER.

Authors:  Yujin Wu; Charles L Brooks Iii
Journal:  J Comput Aided Mol Des       Date:  2022-08-19       Impact factor: 4.179

7.  Virtual Screening Based on Machine Learning Explores Mangrove Natural Products as KRASG12C Inhibitors.

Authors:  Lianxiang Luo; Tongyu Zheng; Qu Wang; Yingling Liao; Xiaoqi Zheng; Ai Zhong; Zunnan Huang; Hui Luo
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-08

8.  Protocetraric and Salazinic Acids as Potential Inhibitors of SARS-CoV-2 3CL Protease: Biochemical, Cytotoxic, and Computational Characterization of Depsidones as Slow-Binding Inactivators.

Authors:  Lorenza Fagnani; Lisaurora Nazzicone; Pierangelo Bellio; Nicola Franceschini; Donatella Tondi; Andrea Verri; Sabrina Petricca; Roberto Iorio; Gianfranco Amicosante; Mariagrazia Perilli; Giuseppe Celenza
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-04

9.  Structure-Based Design and Biological Evaluation of Novel Caspase-2 Inhibitors Based on the Peptide AcVDVAD-CHO and the Caspase-2-Mediated Tau Cleavage Sequence YKPVD314.

Authors:  Merlin Bresinsky; Jessica M Strasser; Bernadette Vallaster; Peng Liu; William M McCue; Jessica Fuller; Alexander Hubmann; Gurpreet Singh; Kathryn M Nelson; Matthew E Cuellar; Carrie M Wilmot; Barry C Finzel; Karen H Ashe; Michael A Walters; Steffen Pockes
Journal:  ACS Pharmacol Transl Sci       Date:  2022-01-05

10.  An automatic pipeline for the design of irreversible derivatives identifies a potent SARS-CoV-2 Mpro inhibitor.

Authors:  Daniel Zaidman; Paul Gehrtz; Mihajlo Filep; Daren Fearon; Ronen Gabizon; Alice Douangamath; Jaime Prilusky; Shirly Duberstein; Galit Cohen; C David Owen; Efrat Resnick; Claire Strain-Damerell; Petra Lukacik; Haim Barr; Martin A Walsh; Frank von Delft; Nir London
Journal:  Cell Chem Biol       Date:  2021-06-25       Impact factor: 8.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.